

## Curriculum Vitae



**Name** Wei-Chen Lu 魯維丞

**Birthday** June 21, 1982

**Institutional Address** Oncology Center and Department of Oncology,  
National Taiwan University Hospital, Yunlin branch  
No.95, 19th Neighborhood, Lianshih, Huwei Township, Yunlin  
County 63247, Taiwan  
Tel: 05-6330002  
Email: [b89401007@ntu.edu.tw](mailto:b89401007@ntu.edu.tw)

Education	Degree	Institution	Year
	M.D.	College of Medicine, National Taiwan University	2000-2007

  

Work Experience	Position	Institution	Time
	Director	Division of Medical Oncology, Department of Oncology, National Taiwan University Hospital Yunlin Branch	2021 Aug-
	Vice Director	Oncology Center, National Taiwan University Hospital Yunlin Branch,	2016-
	Attending Physician , Medical Oncology	Department of Oncology, National Taiwan University Hospital Yunlin Branch	2014 July-
	Fellow, Medical Oncology	Department of Oncology, National Taiwan University Hospital	2011 Jul- 2014 Jun
	Resident, Internal Medicine	Department of Internal Medicine, National Taiwan University Hospital	2008 Jul- 2011 Jun

Summary of qualification	Time
Board of Medical Oncology	2013-
Board of Internal Medicine	2011-

Professional Membership	Time
European Society for Medical Oncology(ESMO)	2017-

American Society of Clinical Oncology(ASCO)	2013-
Taiwan Oncology Society(TOS)	2011-
Society of Internal Medicine of Taiwan	2011-

---

**Awards**      第 27 屆台灣癌症聯合學術年會臨床組優良論文獎(2022)

---

**Clinical**      head and neck cancer, nasopharyngeal carcinoma, esophageal cancer,

**Interest**      lung cancer, GI cancer, prostate cancer

---

**Publication:**

1. Jia-Zheng Huang, **Wei-Chen Lu**, Bo-Ching Lee, Exposed Embolic Coils Observed in a 64-Year-Old Male With Head and Neck Cancer Following Transarterial Embolization for Carotid Blowout Syndrome, Case Rep Oncol Med. 2024 May 13:2024:7925511
2. Hsing-Wu Chen, Yao-Wen Kuo, Chung-Yu Chen, Chin-Hao Chang, Su-Mei Wang, Ying-Chun Chien, **Wei-Chen Lu**, Jo-Pai Chen, Cheng-Yu Chang, Yu-Feng Wei, Shih-Chieh Chang, Chin-Chung Shu, Jann-Yuan Wang, Wei-Yu Liao, Hao-Chien Wang, Chong-Jen Yu, Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy, Oncologist. 2024 Jan 16
3. Hung-Ming Wang, Pei-Jen Lou, Muh-Hwa Yang, Tein-Hua Chen, Ming-Yu Lien, Jin-Ching Lin, Jo-Pai Chen, **Wei-Chen Lu**, Hsueh-Ju Lu, Tai-Lin Huang, Chia-Jui Yen, Shang-Yin Wu, Hui-Ching Wang, and Meng-Che Hsieh, Cetuximab Treatment beyond Progression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Nationwide Population-Based Study (THNS-2021-08), Target Oncol. 2024; 19(1): 51–58.
4. Hsueh-Ju Lu MD, PhD, Meng-Che Hsieh MD, Hung-Ming Wang MD, Jason Chia-Hsun Hsieh MD, PhD, Chia-Jui Yen MD, PhD, Shang-Yin Wu MD, Huai-Cheng Huang MD, Hui-Ching Wang MD, Pen-Yuan Chu MD, Tien-Hua Chen MD, Chih-Yen Chien MD, Tai-Lin Huang MD, PhD, Yi-Fang Chang MD, PhD, Chun-Hung Hua MD, Ming-Yu Lien MD, PhD, Jo-Pai Chen MD, **Wei-Chen Lu** MD, Jin-Ching Lin MD, PhD, Chen-Chi Wang MD, Yi-Chun Liu MD, Muh-Hwa Yang MD, PhD, Pei-Jen Lou MD, PhD, Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma: A real-world study using Taiwan Head Neck Society registry database, Head and Neck 2024

5. Chou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang, Bo-Wen Lin, Hong-Hwa Chen, Yao-Yu Hsieh, Hung-Chih Hsu, Meng-Che Hsieh, Tao-Wei Ke, Feng-Che Kuan, Chih-Chien Wu, **Wei-Chen Lu**, Yu-Li Su, Yi-Hsin Liang, Joe-Bin Chen, Hsuan-Yuan Huang, Hsiang-Lin Tsai, and Jaw-Yuan Wang, Survival benefit of metastasectomy in first-line cetuximab therapy in patients with RAS wild-type metastatic colorectal cancer: a nationwide registry, *Am J Cancer Res.* 2023; 13(12): 6333–6345
6. Yu-Tang Chang, Chou-Chen Chen, Shih-Ching Chang, Yu-Yao Chang, Bo-Wen Lin, Hong-Hwa Chen, Yao-Yu Hsieh, Hung-Chih Hsu, Meng-Che Hsieh, Feng-Che Kuan, Chih-Chien Wu, **Wei-Chen Lu**, Yu-Li Su, Yi-Hsin Liang, Joe-Bin Chen, Shuan-Yuan Huang, Ching-Wen Huang, Jaw-Yuan Wang, Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study, *Nutrients.* 2023 Jun 30;15(13):2971. doi: 10.3390/nu15132971.
7. **Wei-Chen Lu**, Wei-Li Ma, Hsu Wu, Fu-Jen Hsueh, Hsing-Wu Chen, Keng-Man Chiang, Tsui-Mai Kao, Jo-Pai Chen, Beyond The EXTREME Study: Treatment Decisions for Patients with Head and Neck Squamous Cell Carcinoma Which Progress during or within 6 months after Completion of Concurrent Chemoradiotherapy, 2022 *TJCC poster presentation*
8. Muh-Hwa Yang, Chen Tien Hua, Meng-Che Hsieh, Huai-Cheng Huang, Chih-Yen Chien, Tai-Lin Huang, Chun-Hung Hua, Ming-Yu Lien, Hui-Ching Wang, Hsueh-Ju Lu, Chia-Jui Yen, Shang-Yin Wu, Jo-Pai Chen, **Wei-Chen Lu**, Jin-Ching Lin, Chen-Chi Wang, Yi-Chun Liu, Hung-Ming Wang, Jason, Chia-Hsun Heieh, Pei-Jen Lou, A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen ASCO 2022 poster *Journal of Clinical Oncology* 40, no. 16\_suppl (June 01, 2022) e18013-e18013
9. **Wei-Chen Lu**, Wei-Li Ma, Hsu Wu, Fu-Jen Hsueh, Jo-Pai Chen, Beyond The EXTREME Study: Extremely Poor Prognosis for Patients with Head and Neck Squamous Cell Carcinoma Which Progress within 3 months after Completion of Concurrent Chemoradiotherapy, 2019 *TJCC e-poster*
10. **Wei-Chen Lu**, Chia-Chi Lin, James Chih-Hsin Yang, Angiokinase Inhibitors in Non-small Cell Lung

